Find It Early Act
Summary
The Find It Early Act (S.1410), introduced in April 2025, would mandate no-cost-sharing coverage for advanced breast imaging for high-risk individuals and those with dense breast tissue. The bill is in early legislative stages (referred to committee) with no funding authorized. Real market data shows GEHC has fallen 14.88% in the last 7 days to $59.49, near its 52-week low, while UNH has surged 41.62% over 30 days to $370.74—moves driven by factors unrelated to this early-stage bill.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.1410 is an early-stage bill (referred to committee April 2025) with no subsequent action—very low passage probability in the 119th Congress.
- 2.The bill authorizes zero federal spending; it mandates private insurance coverage changes, shifting costs to insurers and premium payers.
- 3.GEHC is a structural beneficiary (imaging equipment manufacturer), but its recent 14.88% weekly drop to $59.49 is driven by unrelated factors.
- 4.UNH is a structural loser (largest health insurer), but its 41.62% monthly surge reflects other market dynamics, not this bill.
- 5.Actual legislative impact is years away—this analysis identifies structural positioning, not near-term trading catalysts.
Market Implications
The Find It Early Act is a long-duration legislative tail risk for health insurers and a tailwind for diagnostic imaging companies. However, with zero legislative momentum and no action in a year, the market has correctly priced this bill at near-zero probability. GEHC's current price of $59.49 (near 52-week low of $58.75) reflects bearish sentiment on the med-tech sector, not anticipation of this bill. UNH at $370.74 (near top of $234.60–$411.99 52-week range) is being driven by separate dynamics, possibly favorable Medicare Advantage rate news or earnings. Investors should treat this bill as structural context for long-term positioning, not a near-term trading signal. The early-stage status and lack of committee action mean other legislative priorities (appropriations, must-pass bills) will consume the remainder of the 119th Congress's health policy bandwidth.
Full Analysis
-
What happened: On April 10, 2025, Sen. Klobuchar (D-MN) introduced S.1410, the 'Find It Early Act', with 8 cosponsors. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions. It has a companion bill (HR6182) referred to subcommittee in the House. This is an early-stage bill with no further action in the year since introduction.
-
The money trail: S.1410 does not authorize or appropriate any federal funding. It is a coverage mandate—it requires private health plans to cover additional breast imaging without cost-sharing. The cost is borne by insurers and, ultimately, premium payers. No taxpayer dollars are involved. The mechanism amends Section 2713 of the Public Health Service Act (the ACA preventive services mandate) to add a new required benefit category.
-
Structural winners and losers: Winners are diagnostic imaging equipment manufacturers ($GEHC) and independent diagnostic lab operators ($DGX, $LH) that would see increased scan volumes as patient cost barriers are removed. Losers are health insurers ($UNH) that must absorb the full cost of these additional screenings. The impact is proportional to each company's exposure: GEHC is a pure-play med-tech with strong breast imaging product lines; DGX and LH have significant mammography and imaging service volume; UNH, as the largest insurer, faces the largest absolute claims increase.
-
Real market data analysis: GEHC has collapsed 14.88% in 7 days to $59.49, now trading just above its 52-week low of $58.75. UNH has surged 41.62% in 30 days to $370.74. These dramatic moves are unrelated to S.1410. GEHC's decline may reflect broader healthcare med-tech weakness or company-specific issues (earnings, guidance). UNH's rally could be tied to a separate legislative or regulatory event not covered here. The bill's early stage means it has not been a price driver for any ticker.
-
Timeline: S.1410 has sat without action since its April 2025 referral. To become law, it must pass the Senate HELP Committee, pass the full Senate, pass the House (where companion HR6182 also awaits committee action), and be signed by the President. With no hearings, markups, or further cosponsors added, this bill has very low momentum. Passage probability in this Congress is below 10%. The 2026 midterm elections also create a narrowing legislative window.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandate requiring health plans to cover screening and diagnostic imaging at no cost-sharing for high-risk individuals and those with dense breast tissue, with no frequency limitations.
Who must act
Group health plans and health insurance issuers subject to Section 2713 of the Public Health Service Act.
What happens
Insurers must pay 100% of allowable costs for advanced breast imaging (2D/3D mammograms, breast ultrasound, breast MRI, molecular breast imaging) for the expanded eligible population, eliminating patient cost-sharing. This increases total imaging procedure volume by removing patient price sensitivity.
Stock impact
$GEHC is a leading manufacturer of mammography, breast ultrasound, and breast MRI systems. Higher utilization of these devices drives recurring service contract revenue and consumables sales. $GEHC's installed base in US hospitals and imaging centers would see increased scan volumes, supporting equipment replacement cycles and service revenue growth.
What the bill does
Same mandate as above. Increased demand for screening and diagnostic breast imaging flows directly to independent diagnostic service providers.
Who must act
Health plans must reimburse diagnostic imaging providers at contracted rates without patient cost-sharing.
What happens
Quest Diagnostics' advanced imaging and radiology service volume increases as the eligible population (high-risk + dense breast tissue) receives no-cost access. The elimination of out-of-pocket costs drives utilization among price-sensitive patients.
Stock impact
Quest Diagnostics operates a national network of patient service centers and performs a significant volume of mammography and breast imaging. Expanded coverage for high-risk patients increases revenue per patient and total imaging encounters. Quest's breast health business is a direct beneficiary of volume increases from eliminating cost barriers.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $526M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $782M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →